Trial Outcomes & Findings for Bevacizumab in Treating Patients With Recurrent or Progressive Meningiomas (NCT NCT01125046)

NCT ID: NCT01125046

Last Updated: 2021-01-22

Results Overview

Progression Free Survival (PFS) of patients with recurrent or progressive benign and atypical/malignant Meningiomas (grades I-III), despite prior therapy treated with bevacizumab will be defined from the time of registration to the study until the time of first documentation of progressive disease or death from any cause. Progressive disease will be assessed based on the Macdonald Criteria and is defined as 25% increase in the sum of products of all measurable lesions over smallest sum observed (over baseline if no decrease) using the same techniques as baseline, or clear worsening of any evaluable disease, OR appearance of any new lesion/site, OR clear worsening or failure to return for evaluation due to death or deteriorating condition (unless clearly unrelated to this cancer).

• Recruitment status: COMPLETED
• Study phase: PHASE2
• Target enrollment: 50 participants
• Primary outcome timeframe: From the start of treatment and up until 6 months of treatment or follow up
• Results posted on: 2021-01-22

Participant Flow

The study opened for accrual on May 19, 2010 with an accrual goal of up to 50 patients. First patient started treatment on 6/17/2010. The study was closed permanently to further enrollment on September 24, 2013 when accrual was met.

Participant milestones

Measure	Treatment With Bevacizumab Patients receive bevacizumab IV over 30-90 minutes every 2 weeks for 6 months (1 cycle = 28 days with two doses of bevacizumab). Patients may then receive bevacizumab IV every 3 weeks for up to 12 months (1 cycle = 42 days) or stay on the 2 week cycle at the discretion of the treating physician. Treatment continues in the absence of disease progression or unacceptable toxicity. After 12 months of treatment patients may continue on bevacizumab at the discretion of their treating physician. bevacizumab: Given IV
First 6 Months of Treatment STARTED	50
First 6 Months of Treatment COMPLETED	36
First 6 Months of Treatment NOT COMPLETED	14
Continued Treatment After 6 Months STARTED	36
Continued Treatment After 6 Months COMPLETED	33
Continued Treatment After 6 Months NOT COMPLETED	3
Follow-up/Data Cut Off Point STARTED	49
Follow-up/Data Cut Off Point COMPLETED	16
Follow-up/Data Cut Off Point NOT COMPLETED	33

Reasons for withdrawal

Measure	Treatment With Bevacizumab Patients receive bevacizumab IV over 30-90 minutes every 2 weeks for 6 months (1 cycle = 28 days with two doses of bevacizumab). Patients may then receive bevacizumab IV every 3 weeks for up to 12 months (1 cycle = 42 days) or stay on the 2 week cycle at the discretion of the treating physician. Treatment continues in the absence of disease progression or unacceptable toxicity. After 12 months of treatment patients may continue on bevacizumab at the discretion of their treating physician. bevacizumab: Given IV
First 6 Months of Treatment Death	1
First 6 Months of Treatment Withdrawal by Subject	2
First 6 Months of Treatment Non-compliance	1
First 6 Months of Treatment Surgery	1
First 6 Months of Treatment Progressive Disease	7
First 6 Months of Treatment Adverse Event	2
Continued Treatment After 6 Months Progressive Disease	2
Continued Treatment After 6 Months Adverse Event	1
Follow-up/Data Cut Off Point Death	29
Follow-up/Data Cut Off Point Lost to Follow-up	4

Baseline Characteristics

Bevacizumab in Treating Patients With Recurrent or Progressive Meningiomas

Baseline characteristics by cohort

Measure	Treatment With Bevacizumab n=50 Participants Patients receive bevacizumab IV over 30-90 minutes every 2 weeks for 6 months (1 cycle = 28 days with two doses of bevacizumab). Patients may then receive bevacizumab IV every 3 weeks for up to 12 months (1 cycle = 42 days) or stay on the 2 week cycle at the discretion of the treating physician. Treatment continues in the absence of disease progression or unacceptable toxicity. After 12 months of treatment patients may continue on bevacizumab at the discretion of their treating physician. bevacizumab: Given IV
Age, Categorical <=18 years	0 Participants n=5 Participants
Age, Categorical Between 18 and 65 years	37 Participants n=5 Participants
Age, Categorical >=65 years	13 Participants n=5 Participants
Sex: Female, Male Female	26 Participants n=5 Participants
Sex: Female, Male Male	24 Participants n=5 Participants
Ethnicity (NIH/OMB) Hispanic or Latino	5 Participants n=5 Participants
Ethnicity (NIH/OMB) Not Hispanic or Latino	45 Participants n=5 Participants
Ethnicity (NIH/OMB) Unknown or Not Reported	0 Participants n=5 Participants
Race (NIH/OMB) American Indian or Alaska Native	0 Participants n=5 Participants
Race (NIH/OMB) Asian	1 Participants n=5 Participants
Race (NIH/OMB) Native Hawaiian or Other Pacific Islander	0 Participants n=5 Participants
Race (NIH/OMB) Black or African American	2 Participants n=5 Participants
Race (NIH/OMB) White	47 Participants n=5 Participants
Race (NIH/OMB) More than one race	0 Participants n=5 Participants
Race (NIH/OMB) Unknown or Not Reported	0 Participants n=5 Participants
Region of Enrollment United States	50 Participants n=5 Participants
Stage of Disease (at study entry) Stage I	15 Participants n=5 Participants
Stage of Disease (at study entry) Stage II	22 Participants n=5 Participants
Stage of Disease (at study entry) Stage III	13 Participants n=5 Participants
Diagnosis Meningioma	42 Participants n=5 Participants
Diagnosis Hemangiopericytoma	4 Participants n=5 Participants
Diagnosis Acoustic Neuroma/Vestibular Schwannoma	4 Participants n=5 Participants

PRIMARY outcome

Timeframe: From the start of treatment and up until 6 months of treatment or follow up

Population: PFS was analyzed based on grading of meningioma due to the difference in prognosis of grades to provide meaningful results. In general, grade I tumor grows slowly, grade II tumor grows more quickly and is often called atypical meningioma, and grade III tumor grows and spreads very quickly and is often called anaplastic or malignant meningioma.

Progression Free Survival (PFS) of patients with recurrent or progressive benign and atypical/malignant Meningiomas (grades I-III), despite prior therapy treated with bevacizumab will be defined from the time of registration to the study until the time of first documentation of progressive disease or death from any cause. Progressive disease will be assessed based on the Macdonald Criteria and is defined as 25% increase in the sum of products of all measurable lesions over smallest sum observed (over baseline if no decrease) using the same techniques as baseline, or clear worsening of any evaluable disease, OR appearance of any new lesion/site, OR clear worsening or failure to return for evaluation due to death or deteriorating condition (unless clearly unrelated to this cancer).

Outcome measures

Measure	Treatment With Bevacizumab n=42 Participants Patients receive bevacizumab IV over 30-90 minutes every 2 weeks for 6 months (1 cycle = 28 days with two doses of bevacizumab). Patients may then receive bevacizumab IV every 3 weeks for up to 12 months (1 cycle = 42 days) or stay on the 2 week cycle at the discretion of the treating physician. Treatment continues in the absence of disease progression or unacceptable toxicity. After 12 months of treatment patients may continue on bevacizumab at the discretion of their treating physician. bevacizumab: Given IV
Progression Free Survival (PFS) of Patients With Recurrent or Progressive Meningiomas Treated With Bevacizumab at 6 Months Grade I Meningioma	93 percentage of patients Interval 61.0 to 99.0
Progression Free Survival (PFS) of Patients With Recurrent or Progressive Meningiomas Treated With Bevacizumab at 6 Months Grade II Meningioma	85 percentage of patients Interval 61.0 to 95.0
Progression Free Survival (PFS) of Patients With Recurrent or Progressive Meningiomas Treated With Bevacizumab at 6 Months Grade III Meningioma	51 percentage of patients Interval 22.0 to 75.0
Progression Free Survival (PFS) of Patients With Recurrent or Progressive Meningiomas Treated With Bevacizumab at 6 Months Grade II/III Meningioma	73 percentage of patients Interval 54.0 to 85.0

SECONDARY outcome

Timeframe: From start of treatment and approximately every 8 weeks for up to approximately 5 years ( maximum duration any one patient was on treatment)

Best Response of patients treated with bevacizumab with diagnosis of any of the following: meningioma, hemangiopericytoma, hemangioblastoma, acustic neuroma or schwanoma will be assessed using the MacDonald Criteria.

In general:

Complete Response-Complete disappearance of all measurable and evaluable disease. No new lesions. No evidence of non-evaluable disease. Patients not on steroids.

Partial Response-50% or greater decrease under baseline in the sum of products of perpendicular diameters of the two largest measurable lesions. No progression of evaluable disease. No new lesions.

Stable Disease-Not CR or PR or PD. Progressive disease (PD)-25% increase in the sum of products of all measurable lesions over smallest sum observed, OR clear worsening of any evaluable disease, OR appearance of any new lesion/site, OR clear worsening or failure to return for evaluation due to death/deteriorating condition

Outcome measures

Measure	Treatment With Bevacizumab n=50 Participants Patients receive bevacizumab IV over 30-90 minutes every 2 weeks for 6 months (1 cycle = 28 days with two doses of bevacizumab). Patients may then receive bevacizumab IV every 3 weeks for up to 12 months (1 cycle = 42 days) or stay on the 2 week cycle at the discretion of the treating physician. Treatment continues in the absence of disease progression or unacceptable toxicity. After 12 months of treatment patients may continue on bevacizumab at the discretion of their treating physician. bevacizumab: Given IV
Number of Patients With Each Response Complete Response	0 Participants
Number of Patients With Each Response Partial Response	2 Participants
Number of Patients With Each Response Stable Disease	43 Participants
Number of Patients With Each Response Progressive Diseaase	4 Participants
Number of Patients With Each Response Death	1 Participants

SECONDARY outcome

Timeframe: Every 2 weeks or 3 weeks while on treatment up to 30 days after the last dose. The maximum duration any one patient was on treatment was approximately 5 years.

Safety of bevacizumab in patients with diagnosis of any of the following: meningioma, hemangiopericytoma, hemangioblastoma, acustic neuroma or schwanoma, will be assessed by collecting the number of adverse events experienced by patients that were determined to be at least possibly related to bevacaumab and assessed as a grade 3 or 4. AEs will be graded according to the NCI Common Terminology Criteria for Adverse Events (CTCAE) v4.0.

In general, AEs will be graded as follows:

Grade 1 - Mild Grade 2 - Moderate Grade 3 - Severe Grade 4 - Life-threatening Grade 5 - Fatal

Outcome measures

Measure	Treatment With Bevacizumab n=50 Participants Patients receive bevacizumab IV over 30-90 minutes every 2 weeks for 6 months (1 cycle = 28 days with two doses of bevacizumab). Patients may then receive bevacizumab IV every 3 weeks for up to 12 months (1 cycle = 42 days) or stay on the 2 week cycle at the discretion of the treating physician. Treatment continues in the absence of disease progression or unacceptable toxicity. After 12 months of treatment patients may continue on bevacizumab at the discretion of their treating physician. bevacizumab: Given IV
Safety Profile of Bevacizumab Hypertension	10 Participants
Safety Profile of Bevacizumab Hyponatremia	2 Participants
Safety Profile of Bevacizumab Proteinuria	2 Participants
Safety Profile of Bevacizumab Ataxia	1 Participants
Safety Profile of Bevacizumab Pancreatitis	1 Participants
Safety Profile of Bevacizumab Nausea/Vomiting	1 Participants
Safety Profile of Bevacizumab Elevated Lipase	1 Participants
Safety Profile of Bevacizumab Anemia	1 Participants
Safety Profile of Bevacizumab Infection	1 Participants
Safety Profile of Bevacizumab Muscle weakness	1 Participants
Safety Profile of Bevacizumab Epistaxis (Nosebleed)	1 Participants
Safety Profile of Bevacizumab Thrombus/embolism	1 Participants
Safety Profile of Bevacizumab Fatigue	1 Participants

SECONDARY outcome

Timeframe: At baseline and every 8 weeks until disease progression or death. The maximum duration any one patient was on treatment was approximately 5 years.

Tissue was collected for VEGF, VEGRfR2 and HER2 at baseline. Patients underwent radiological assessments every 8 weeks during treatment to determine disease status to treatment (complete response/partial response/stable disease/progressive disease). The level of VEGF, VEGRfR2 and HER2 marker expression was compared with the response as determined at the time of disease progression or death. Immunohistochemistry (IHC) will be analyzed using blobfinder technology.

Each sample was given a score for the markers expression in the tissue 1, 2 or 3 (1=+, 2=++, 3=+++, from low to high) and a percentage 0-100% (low to high) of how much tissue it was expressed in.

If score = 0 and percentage =0 the sample was negative for that marker. If score = 1 and percentage =10% the marker had an expression of 1 (+) in 10 percent of the tissue and so forth.

The data is shown by patient and their best response to treatment with their score and expression for VEGF, VEGRfR2 and HER2.

Outcome measures

Measure	Treatment With Bevacizumab n=42 Participants Patients receive bevacizumab IV over 30-90 minutes every 2 weeks for 6 months (1 cycle = 28 days with two doses of bevacizumab). Patients may then receive bevacizumab IV every 3 weeks for up to 12 months (1 cycle = 42 days) or stay on the 2 week cycle at the discretion of the treating physician. Treatment continues in the absence of disease progression or unacceptable toxicity. After 12 months of treatment patients may continue on bevacizumab at the discretion of their treating physician. bevacizumab: Given IV
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #01/Partial Response : VEGF Score	1 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #01/Partial Response : VEGF Expression	30 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #01/Partial Response : VEGRfR2 Score	1 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #01/Partial Response : VEGRfR2 Expression	10 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #01/Partial Response : HER2 Score	0 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #01/Partial Response : HER2 Expression	0 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #02/Stable Disease : VEGF Score	2 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #02/Stable Disease : VEGF Expression	80 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #02/Stable Disease : VEGRfR2 Score	1 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #02/Stable Disease : VEGRfR2 Expression	10 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #02/Stable Disease : HER2 Score	1 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #02/Stable Disease : HER2 Expression	50 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #03/Stable Disease : VEGF Score	2 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #03/Stable Disease : VEGF Expression	80 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #03/Stable Disease : VEGRfR2 Score	1 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #03/Stable Disease : VEGRfR2 Expression	20 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #03/Stable Disease : HER2 Score	0 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #03/Stable Disease : HER2 Expression	0 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #04/Stable Disease : VEGF Score	2 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #04/Stable Disease : VEGF Expression	80 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #04/Stable Disease : VEGRfR2 Score	2 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #04/Stable Disease : VEGRfR2 Expression	10 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #04/Stable Disease : HER2 Score	1 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #04/Stable Disease : HER2 Expression	10 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #07/Stable Disease : VEGF Score	2 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #07/Stable Disease : VEGF Expression	60 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #07/Stable Disease : VEGRfR2 Score	2 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #07/Stable Disease : VEGRfR2 Expression	10 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #07/Stable Disease : HER2 Score	0 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #07/Stable Disease : HER2 Expression	0 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #08/death : VEGF Score	2 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #08/death : VEGF Expression	70 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #08/death : VEGRfR2 Score	1 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #08/death : VEGRfR2 Expression	10 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #08/death : HER2 Score	1 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #08/death : HER2 Expression	30 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #09/Stable Disease : VEGF Score	2 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #09/Stable Disease : VEGF Expression	60 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #09/Stable Disease : VEGRfR2 Score	0 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #09/Stable Disease : VEGRfR2 Expression	0 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #09/Stable Disease : HER2 Score	0 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #09/Stable Disease : HER2 Expression	0 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #10/Stable Disease : VEGF Score	3 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #10/Stable Disease : VEGF Expression	70 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #10/Stable Disease : VEGRfR2 Score	1 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #10/Stable Disease : VEGRfR2 Expression	30 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #10/Stable Disease : HER2 Score	0 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #10/Stable Disease : HER2 Expression	0 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #11a/Stable Disease : VEGF Score	3 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #11a/Stable Disease : VEGF Expression	80 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #11a/Stable Disease : VEGRfR2 Score	1 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #11a/Stable Disease : VEGRfR2 Expression	10 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #11a/Stable Disease : HER2 Score	1 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #11a/Stable Disease : HER2 Expression	5 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #12/Stable Disease : VEGF Score	1 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #12/Stable Disease : VEGF Expression	20 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #12/Stable Disease : VEGRfR2 Score	1 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #12/Stable Disease : VEGRfR2 Expression	50 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #12/Stable Disease : HER2 Score	0 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #12/Stable Disease : HER2 Expression	0 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #13/Stable Disease : VEGF Score	2 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #13/Stable Disease : VEGF Expression	50 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #13/Stable Disease : VEGRfR2 Score	2 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #13/Stable Disease : VEGRfR2 Expression	70 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #13/Stable Disease : HER2 Score	0 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #13/Stable Disease : HER2 Expression	0 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #15/Stable Disease : VEGF Score	2 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #15/Stable Disease : VEGF Expression	80 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #15/Stable Disease : VEGRfR2 Score	1 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #15/Stable Disease : VEGRfR2 Expression	50 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #15/Stable Disease : HER2 Score	0 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #15/Stable Disease : HER2 Expression	0 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #16/Progressive Disease : VEGF Score	3 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #16/Progressive Disease : VEGF Expression	90 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #16/Progressive Disease : VEGRfR2 Score	1 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #16/Progressive Disease : VEGRfR2 Expression	50 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #16/Progressive Disease : HER2 Score	0 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #16/Progressive Disease : HER2 Expression	0 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #17/Stable Disease : VEGF Score	3 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #17/Stable Disease : VEGF Expression	100 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #17/Stable Disease : VEGRfR2 Score	0 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #17/Stable Disease : VEGRfR2 Expression	0 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #17/Stable Disease : HER2 Score	0 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #17/Stable Disease : HER2 Expression	0 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #19/Stable Disease : VEGF Score	2 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #19/Stable Disease : VEGF Expression	50 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #19/Stable Disease : VEGRfR2 Score	1 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #19/Stable Disease : VEGRfR2 Expression	20 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #19/Stable Disease : HER2 Score	1 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #19/Stable Disease : HER2 Expression	10 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #020/Stable Disease : VEGF Score	1 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #020/Stable Disease : VEGF Expression	80 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #020/Stable Disease : VEGRfR2 Score	1 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #020/Stable Disease : VEGRfR2 Expression	30 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #020/Stable Disease : HER2 Score	1 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #020/Stable Disease : HER2 Expression	10 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #120/Stable Disease : VEGF Score	1 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #120/Stable Disease : VEGF Expression	50 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #120/Stable Disease : VEGRfR2 Score	1 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #120/Stable Disease : VEGRfR2 Expression	10 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #120/Stable Disease : HER2 Score	0 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #120/Stable Disease : HER2 Expression	0 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #21/Progressive Disease : VEGF Score	1 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #21/Progressive Disease : VEGF Expression	70 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #21/Progressive Disease : VEGRfR2 Score	1 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #21/Progressive Disease : VEGRfR2 Expression	30 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #21/Progressive Disease : HER2 Score	0 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #21/Progressive Disease : HER2 Expression	0 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #22/Stable Disease : VEGF Score	2 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #22/Stable Disease : VEGF Expression	70 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #22/Stable Disease : VEGRfR2 Score	0 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #22/Stable Disease : VEGRfR2 Expression	0 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #22/Stable Disease : HER2 Score	0 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #22/Stable Disease : HER2 Expression	0 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #23/Stable Disease : VEGF Score	2 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #23/Stable Disease : VEGF Expression	80 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #23/Stable Disease : VEGRfR2 Score	1 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #23/Stable Disease : VEGRfR2 Expression	5 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #23/Stable Disease : HER2 Score	0 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #23/Stable Disease : HER2 Expression	0 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #26/Stable Disease : VEGF Score	3 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #26/Stable Disease : VEGF Expression	90 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #26/Stable Disease : VEGRfR2 Score	2 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #26/Stable Disease : VEGRfR2 Expression	50 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #26/Stable Disease : HER2 Score	0 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #26/Stable Disease : HER2 Expression	0 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #28/Stable Disease : VEGF Score	1 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #28/Stable Disease : VEGF Expression	50 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #28/Stable Disease : VEGRfR2 Score	0 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #28/Stable Disease : VEGRfR2 Expression	0 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #35/Stable Disease : HER2 Expression	0 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #28/Stable Disease : HER2 Score	0 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #28/Stable Disease : HER2 Expression	0 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #29/Stable Disease : VEGF Score	1 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #29/Stable Disease : VEGF Expression	80 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #29/Stable Disease : VEGRfR2 Score	1 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #29/Stable Disease : VEGRfR2 Expression	20 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #29/Stable Disease : HER2 Score	0 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #29/Stable Disease : HER2 Expression	0 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #30/Stable Disease : VEGF Score	2 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #30/Stable Disease : VEGF Expression	70 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #30/Stable Disease : VEGRfR2 Score	0 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #30/Stable Disease : VEGRfR2 Expression	0 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #30/Stable Disease : HER2 Score	0 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #30/Stable Disease : HER2 Expression	0 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #31/Stable Disease : VEGF Score	2 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #31/Stable Disease : VEGF Expression	90 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #31/Stable Disease : VEGRfR2 Score	0 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #31/Stable Disease : VEGRfR2 Expression	0 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #31/Stable Disease : HER2 Score	0 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #31/Stable Disease : HER2 Expression	0 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #32/Stable Disease : VEGF Score	2 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #32/Stable Disease : VEGF Expression	80 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #32/Stable Disease : VEGRfR2 Score	2 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #32/Stable Disease : VEGRfR2 Expression	50 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #32/Stable Disease : HER2 Score	1 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #32/Stable Disease : HER2 Expression	10 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #33/Progressive Disease : VEGF Score	3 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #33/Progressive Disease : VEGF Expression	70 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #33/Progressive Disease : VEGRfR2 Score	1 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #33/Progressive Disease : VEGRfR2 Expression	10 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #33/Progressive Disease : HER2 Score	0 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #33/Progressive Disease : HER2 Expression	0 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #34/Stable Disease : VEGF Score	3 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #34/Stable Disease : VEGF Expression	70 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #34/Stable Disease : VEGRfR2 Score	0 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #34/Stable Disease : VEGRfR2 Expression	0 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #34/Stable Disease : HER2 Score	0 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #34/Stable Disease : HER2 Expression	0 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #35/Stable Disease : VEGF Score	2 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #35/Stable Disease : VEGF Expression	50 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #35/Stable Disease : VEGRfR2 Score	1 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #35/Stable Disease : VEGRfR2 Expression	50 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #35/Stable Disease : HER2 Score	0 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #37/Stable Disease : VEGF Score	3 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #37/Stable Disease : VEGF Expression	80 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #37/Stable Disease : VEGRfR2 Score	1 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #37/Stable Disease : VEGRfR2 Expression	30 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #37/Stable Disease : HER2 Score	1 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #37/Stable Disease : HER2 Expression	5 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #38/Stable Disease : VEGF Score	1 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #38/Stable Disease : VEGF Expression	80 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #38/Stable Disease : VEGRfR2 Score	1 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #38/Stable Disease : VEGRfR2 Expression	70 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #38/Stable Disease : HER2 Score	0 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #38/Stable Disease : HER2 Expression	0 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #039/Stable Disease : VEGF Score	3 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #039/Stable Disease : VEGF Expression	100 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #039/Stable Disease : VEGRfR2 Score	0 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #039/Stable Disease : VEGRfR2 Expression	0 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #039/Stable Disease : HER2 Score	0 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #039/Stable Disease : HER2 Expression	0 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #40/Stable Disease : VEGF Score	2 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #40/Stable Disease : VEGF Expression	30 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #40/Stable Disease : VEGRfR2 Score	1 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #40/Stable Disease : VEGRfR2 Expression	50 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #40/Stable Disease : HER2 Score	1 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #40/Stable Disease : HER2 Expression	5 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #41/Stable Disease : VEGF Score	2 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #41/Stable Disease : VEGF Expression	70 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #41/Stable Disease : VEGRfR2 Score	3 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #41/Stable Disease : VEGRfR2 Expression	10 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #41/Stable Disease : HER2 Score	2 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #41/Stable Disease : HER2 Expression	10 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #42/Stable Disease : VEGF Score	0 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #42/Stable Disease : VEGF Expression	0 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #42/Stable Disease : VEGRfR2 Score	0 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #42/Stable Disease : VEGRfR2 Expression	0 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #42/Stable Disease : HER2 Score	0 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #42/Stable Disease : HER2 Expression	0 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #43/Stable Disease : VEGF Score	2 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #43/Stable Disease : VEGF Expression	50 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #43/Stable Disease : VEGRfR2 Score	2 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #43/Stable Disease : VEGRfR2 Expression	5 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #43/Stable Disease : HER2 Score	0 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #43/Stable Disease : HER2 Expression	0 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #44/Stable Disease : VEGF Score	0 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #44/Stable Disease : VEGF Expression	0 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #44/Stable Disease : VEGRfR2 Score	1 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #44/Stable Disease : VEGRfR2 Expression	10 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #44/Stable Disease : HER2 Score	0 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #44/Stable Disease : HER2 Expression	0 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #45/Progressive Disease : VEGF Score	2 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #45/Progressive Disease : VEGF Expression	30 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #45/Progressive Disease : VEGRfR2 Score	1 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #45/Progressive Disease : VEGRfR2 Expression	10 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #45/Progressive Disease : HER2 Score	0 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #45/Progressive Disease : HER2 Expression	0 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #47/Partial Response : VEGF Score	2 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #47/Partial Response : VEGF Expression	50 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #47/Partial Response : VEGRfR2 Score	1 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #47/Partial Response : VEGRfR2 Expression	50 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #47/Partial Response : HER2 Score	0 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #47/Partial Response : HER2 Expression	0 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #48/Stable Disease : VEGF Score	1 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #48/Stable Disease : VEGF Expression	50 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #48/Stable Disease : VEGRfR2 Score	1 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #48/Stable Disease : VEGRfR2 Expression	10 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #48/Stable Disease : HER2 Score	0 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #48/Stable Disease : HER2 Expression	0 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #49/Stable Disease : VEGF Score	2 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #49/Stable Disease : VEGF Expression	20 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #49/Stable Disease : VEGRfR2 Score	1 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #49/Stable Disease : VEGRfR2 Expression	70 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #49/Stable Disease : HER2 Score	0 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #49/Stable Disease : HER2 Expression	0 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #50/Stable Disease : VEGF Score	2 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #50/Stable Disease : VEGF Expression	80 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #50/Stable Disease : VEGRfR2 Score	1 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #50/Stable Disease : VEGRfR2 Expression	20 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #50/Stable Disease : HER2 Score	0 score on a scale
Levels of VEGF, VEGRfR2 and HER2 Expression in Tumor Tissue as Compared to Response #50/Stable Disease : HER2 Expression	0 score on a scale

SECONDARY outcome

Timeframe: At 1 year, 2 years, 3 years post treatment initiation

Population: 2 patients were considered lost to follow up at year 2 and year 3 respectively and were not included in the numbers. Data cut off was Dec 2018 and those who had not reached 3 years are not included in the 3 year number of patients alive. No survival data was collected at these timepoints.

Overall Survival (OS) of patients with Recurrent or Progressive Meningiomas Treated with Bevacizumab will be measured from the time of treatment initiation to the study until death from any cause. The raw data of number of patients documented as being alive at 1 year, 2 year, and 3 years post treatment initiation is reported here.

Outcome measures

Measure	Treatment With Bevacizumab n=50 Participants Patients receive bevacizumab IV over 30-90 minutes every 2 weeks for 6 months (1 cycle = 28 days with two doses of bevacizumab). Patients may then receive bevacizumab IV every 3 weeks for up to 12 months (1 cycle = 42 days) or stay on the 2 week cycle at the discretion of the treating physician. Treatment continues in the absence of disease progression or unacceptable toxicity. After 12 months of treatment patients may continue on bevacizumab at the discretion of their treating physician. bevacizumab: Given IV
Number of Patients Alive at 1 Year, 2 Years and 3 Years Post Treatment Initiation (Overall Survival) for Patients With Recurrent or Progressive Meningiomas Treated With Bevacizumab At 1 year	43 Participants
Number of Patients Alive at 1 Year, 2 Years and 3 Years Post Treatment Initiation (Overall Survival) for Patients With Recurrent or Progressive Meningiomas Treated With Bevacizumab At 2 years	31 Participants
Number of Patients Alive at 1 Year, 2 Years and 3 Years Post Treatment Initiation (Overall Survival) for Patients With Recurrent or Progressive Meningiomas Treated With Bevacizumab At 3 years	16 Participants

Adverse Events

Treatment With Bevacizumab

Serious events: 22 serious events

Other events: 50 other events

Deaths: 30 deaths

Serious adverse events

Measure	Treatment With Bevacizumab n=50 participants at risk Patients receive bevacizumab IV over 30-90 minutes every 2 weeks for 6 months (1 cycle = 28 days with two doses of bevacizumab). Patients may then receive bevacizumab IV every 3 weeks for up to 12 months (1 cycle = 42 days) or stay on the 2 week cycle at the discretion of the treating physician. Treatment continues in the absence of disease progression or unacceptable toxicity. After 12 months of treatment patients may continue on bevacizumab at the discretion of their treating physician. bevacizumab: Given IV
Gastrointestinal disorders Pancreatitis	2.0% 1/50 • Adverse events were collected from the time of treatment initiation until 30 days post treatment discontinuation for all patients. Range of cycles of treatment completed by patients was 1-47 where one cycle equals 28 days on bevaciumab every 2 week schedule and 42 days on bevacizumab every 3 weeks. Longest time any patient was on treatment was 5 years. Data that has been collected in the database is reported here. There is still some data entry of other adverse events for a few patient being completed and this Section will be updated accordingly when all data is entered and available for reporting (if applicable).
Nervous system disorders Seizure	10.0% 5/50 • Adverse events were collected from the time of treatment initiation until 30 days post treatment discontinuation for all patients. Range of cycles of treatment completed by patients was 1-47 where one cycle equals 28 days on bevaciumab every 2 week schedule and 42 days on bevacizumab every 3 weeks. Longest time any patient was on treatment was 5 years. Data that has been collected in the database is reported here. There is still some data entry of other adverse events for a few patient being completed and this Section will be updated accordingly when all data is entered and available for reporting (if applicable).
Infections and infestations Anorectal Infection	2.0% 1/50 • Adverse events were collected from the time of treatment initiation until 30 days post treatment discontinuation for all patients. Range of cycles of treatment completed by patients was 1-47 where one cycle equals 28 days on bevaciumab every 2 week schedule and 42 days on bevacizumab every 3 weeks. Longest time any patient was on treatment was 5 years. Data that has been collected in the database is reported here. There is still some data entry of other adverse events for a few patient being completed and this Section will be updated accordingly when all data is entered and available for reporting (if applicable).
Musculoskeletal and connective tissue disorders Muscle weakness	2.0% 1/50 • Adverse events were collected from the time of treatment initiation until 30 days post treatment discontinuation for all patients. Range of cycles of treatment completed by patients was 1-47 where one cycle equals 28 days on bevaciumab every 2 week schedule and 42 days on bevacizumab every 3 weeks. Longest time any patient was on treatment was 5 years. Data that has been collected in the database is reported here. There is still some data entry of other adverse events for a few patient being completed and this Section will be updated accordingly when all data is entered and available for reporting (if applicable).
Nervous system disorders Toxic Metabolic Encephalopathy	2.0% 1/50 • Adverse events were collected from the time of treatment initiation until 30 days post treatment discontinuation for all patients. Range of cycles of treatment completed by patients was 1-47 where one cycle equals 28 days on bevaciumab every 2 week schedule and 42 days on bevacizumab every 3 weeks. Longest time any patient was on treatment was 5 years. Data that has been collected in the database is reported here. There is still some data entry of other adverse events for a few patient being completed and this Section will be updated accordingly when all data is entered and available for reporting (if applicable).
General disorders Epistaxis	2.0% 1/50 • Adverse events were collected from the time of treatment initiation until 30 days post treatment discontinuation for all patients. Range of cycles of treatment completed by patients was 1-47 where one cycle equals 28 days on bevaciumab every 2 week schedule and 42 days on bevacizumab every 3 weeks. Longest time any patient was on treatment was 5 years. Data that has been collected in the database is reported here. There is still some data entry of other adverse events for a few patient being completed and this Section will be updated accordingly when all data is entered and available for reporting (if applicable).
Nervous system disorders Aphasia	2.0% 1/50 • Adverse events were collected from the time of treatment initiation until 30 days post treatment discontinuation for all patients. Range of cycles of treatment completed by patients was 1-47 where one cycle equals 28 days on bevaciumab every 2 week schedule and 42 days on bevacizumab every 3 weeks. Longest time any patient was on treatment was 5 years. Data that has been collected in the database is reported here. There is still some data entry of other adverse events for a few patient being completed and this Section will be updated accordingly when all data is entered and available for reporting (if applicable).
Blood and lymphatic system disorders Anemia	2.0% 1/50 • Adverse events were collected from the time of treatment initiation until 30 days post treatment discontinuation for all patients. Range of cycles of treatment completed by patients was 1-47 where one cycle equals 28 days on bevaciumab every 2 week schedule and 42 days on bevacizumab every 3 weeks. Longest time any patient was on treatment was 5 years. Data that has been collected in the database is reported here. There is still some data entry of other adverse events for a few patient being completed and this Section will be updated accordingly when all data is entered and available for reporting (if applicable).
Injury, poisoning and procedural complications Fracture	2.0% 1/50 • Adverse events were collected from the time of treatment initiation until 30 days post treatment discontinuation for all patients. Range of cycles of treatment completed by patients was 1-47 where one cycle equals 28 days on bevaciumab every 2 week schedule and 42 days on bevacizumab every 3 weeks. Longest time any patient was on treatment was 5 years. Data that has been collected in the database is reported here. There is still some data entry of other adverse events for a few patient being completed and this Section will be updated accordingly when all data is entered and available for reporting (if applicable).
Nervous system disorders Left sided apraxia and numbness	2.0% 1/50 • Adverse events were collected from the time of treatment initiation until 30 days post treatment discontinuation for all patients. Range of cycles of treatment completed by patients was 1-47 where one cycle equals 28 days on bevaciumab every 2 week schedule and 42 days on bevacizumab every 3 weeks. Longest time any patient was on treatment was 5 years. Data that has been collected in the database is reported here. There is still some data entry of other adverse events for a few patient being completed and this Section will be updated accordingly when all data is entered and available for reporting (if applicable).
Musculoskeletal and connective tissue disorders Muscle weakness and spasticity	2.0% 1/50 • Adverse events were collected from the time of treatment initiation until 30 days post treatment discontinuation for all patients. Range of cycles of treatment completed by patients was 1-47 where one cycle equals 28 days on bevaciumab every 2 week schedule and 42 days on bevacizumab every 3 weeks. Longest time any patient was on treatment was 5 years. Data that has been collected in the database is reported here. There is still some data entry of other adverse events for a few patient being completed and this Section will be updated accordingly when all data is entered and available for reporting (if applicable).
Nervous system disorders Left-sided paralysis	2.0% 1/50 • Adverse events were collected from the time of treatment initiation until 30 days post treatment discontinuation for all patients. Range of cycles of treatment completed by patients was 1-47 where one cycle equals 28 days on bevaciumab every 2 week schedule and 42 days on bevacizumab every 3 weeks. Longest time any patient was on treatment was 5 years. Data that has been collected in the database is reported here. There is still some data entry of other adverse events for a few patient being completed and this Section will be updated accordingly when all data is entered and available for reporting (if applicable).
Nervous system disorders RPLS	2.0% 1/50 • Adverse events were collected from the time of treatment initiation until 30 days post treatment discontinuation for all patients. Range of cycles of treatment completed by patients was 1-47 where one cycle equals 28 days on bevaciumab every 2 week schedule and 42 days on bevacizumab every 3 weeks. Longest time any patient was on treatment was 5 years. Data that has been collected in the database is reported here. There is still some data entry of other adverse events for a few patient being completed and this Section will be updated accordingly when all data is entered and available for reporting (if applicable).
Musculoskeletal and connective tissue disorders Pain: Musculoskeletal	2.0% 1/50 • Adverse events were collected from the time of treatment initiation until 30 days post treatment discontinuation for all patients. Range of cycles of treatment completed by patients was 1-47 where one cycle equals 28 days on bevaciumab every 2 week schedule and 42 days on bevacizumab every 3 weeks. Longest time any patient was on treatment was 5 years. Data that has been collected in the database is reported here. There is still some data entry of other adverse events for a few patient being completed and this Section will be updated accordingly when all data is entered and available for reporting (if applicable).
Nervous system disorders Somnolence d/t narcotic overdose	2.0% 1/50 • Adverse events were collected from the time of treatment initiation until 30 days post treatment discontinuation for all patients. Range of cycles of treatment completed by patients was 1-47 where one cycle equals 28 days on bevaciumab every 2 week schedule and 42 days on bevacizumab every 3 weeks. Longest time any patient was on treatment was 5 years. Data that has been collected in the database is reported here. There is still some data entry of other adverse events for a few patient being completed and this Section will be updated accordingly when all data is entered and available for reporting (if applicable).
Musculoskeletal and connective tissue disorders Weakness- Lower Extremity	2.0% 1/50 • Adverse events were collected from the time of treatment initiation until 30 days post treatment discontinuation for all patients. Range of cycles of treatment completed by patients was 1-47 where one cycle equals 28 days on bevaciumab every 2 week schedule and 42 days on bevacizumab every 3 weeks. Longest time any patient was on treatment was 5 years. Data that has been collected in the database is reported here. There is still some data entry of other adverse events for a few patient being completed and this Section will be updated accordingly when all data is entered and available for reporting (if applicable).
Nervous system disorders CNS Cebrovascular Ischemia	2.0% 1/50 • Adverse events were collected from the time of treatment initiation until 30 days post treatment discontinuation for all patients. Range of cycles of treatment completed by patients was 1-47 where one cycle equals 28 days on bevaciumab every 2 week schedule and 42 days on bevacizumab every 3 weeks. Longest time any patient was on treatment was 5 years. Data that has been collected in the database is reported here. There is still some data entry of other adverse events for a few patient being completed and this Section will be updated accordingly when all data is entered and available for reporting (if applicable).
Infections and infestations Infection (ventriculitis)	2.0% 1/50 • Adverse events were collected from the time of treatment initiation until 30 days post treatment discontinuation for all patients. Range of cycles of treatment completed by patients was 1-47 where one cycle equals 28 days on bevaciumab every 2 week schedule and 42 days on bevacizumab every 3 weeks. Longest time any patient was on treatment was 5 years. Data that has been collected in the database is reported here. There is still some data entry of other adverse events for a few patient being completed and this Section will be updated accordingly when all data is entered and available for reporting (if applicable).
Infections and infestations Eye Infection	2.0% 1/50 • Adverse events were collected from the time of treatment initiation until 30 days post treatment discontinuation for all patients. Range of cycles of treatment completed by patients was 1-47 where one cycle equals 28 days on bevaciumab every 2 week schedule and 42 days on bevacizumab every 3 weeks. Longest time any patient was on treatment was 5 years. Data that has been collected in the database is reported here. There is still some data entry of other adverse events for a few patient being completed and this Section will be updated accordingly when all data is entered and available for reporting (if applicable).
Nervous system disorders Headache	2.0% 1/50 • Adverse events were collected from the time of treatment initiation until 30 days post treatment discontinuation for all patients. Range of cycles of treatment completed by patients was 1-47 where one cycle equals 28 days on bevaciumab every 2 week schedule and 42 days on bevacizumab every 3 weeks. Longest time any patient was on treatment was 5 years. Data that has been collected in the database is reported here. There is still some data entry of other adverse events for a few patient being completed and this Section will be updated accordingly when all data is entered and available for reporting (if applicable).
Infections and infestations Viral Bronchitis	2.0% 1/50 • Adverse events were collected from the time of treatment initiation until 30 days post treatment discontinuation for all patients. Range of cycles of treatment completed by patients was 1-47 where one cycle equals 28 days on bevaciumab every 2 week schedule and 42 days on bevacizumab every 3 weeks. Longest time any patient was on treatment was 5 years. Data that has been collected in the database is reported here. There is still some data entry of other adverse events for a few patient being completed and this Section will be updated accordingly when all data is entered and available for reporting (if applicable).
Nervous system disorders Pneymocephalus	2.0% 1/50 • Adverse events were collected from the time of treatment initiation until 30 days post treatment discontinuation for all patients. Range of cycles of treatment completed by patients was 1-47 where one cycle equals 28 days on bevaciumab every 2 week schedule and 42 days on bevacizumab every 3 weeks. Longest time any patient was on treatment was 5 years. Data that has been collected in the database is reported here. There is still some data entry of other adverse events for a few patient being completed and this Section will be updated accordingly when all data is entered and available for reporting (if applicable).
Infections and infestations Wound Infection	2.0% 1/50 • Adverse events were collected from the time of treatment initiation until 30 days post treatment discontinuation for all patients. Range of cycles of treatment completed by patients was 1-47 where one cycle equals 28 days on bevaciumab every 2 week schedule and 42 days on bevacizumab every 3 weeks. Longest time any patient was on treatment was 5 years. Data that has been collected in the database is reported here. There is still some data entry of other adverse events for a few patient being completed and this Section will be updated accordingly when all data is entered and available for reporting (if applicable).
Injury, poisoning and procedural complications Fall	2.0% 1/50 • Adverse events were collected from the time of treatment initiation until 30 days post treatment discontinuation for all patients. Range of cycles of treatment completed by patients was 1-47 where one cycle equals 28 days on bevaciumab every 2 week schedule and 42 days on bevacizumab every 3 weeks. Longest time any patient was on treatment was 5 years. Data that has been collected in the database is reported here. There is still some data entry of other adverse events for a few patient being completed and this Section will be updated accordingly when all data is entered and available for reporting (if applicable).
Injury, poisoning and procedural complications Hip Prosthesis Dislocation	2.0% 1/50 • Adverse events were collected from the time of treatment initiation until 30 days post treatment discontinuation for all patients. Range of cycles of treatment completed by patients was 1-47 where one cycle equals 28 days on bevaciumab every 2 week schedule and 42 days on bevacizumab every 3 weeks. Longest time any patient was on treatment was 5 years. Data that has been collected in the database is reported here. There is still some data entry of other adverse events for a few patient being completed and this Section will be updated accordingly when all data is entered and available for reporting (if applicable).
Nervous system disorders Seizures and cognitive disturbance	2.0% 1/50 • Adverse events were collected from the time of treatment initiation until 30 days post treatment discontinuation for all patients. Range of cycles of treatment completed by patients was 1-47 where one cycle equals 28 days on bevaciumab every 2 week schedule and 42 days on bevacizumab every 3 weeks. Longest time any patient was on treatment was 5 years. Data that has been collected in the database is reported here. There is still some data entry of other adverse events for a few patient being completed and this Section will be updated accordingly when all data is entered and available for reporting (if applicable).
Metabolism and nutrition disorders Hyponatremia	2.0% 1/50 • Adverse events were collected from the time of treatment initiation until 30 days post treatment discontinuation for all patients. Range of cycles of treatment completed by patients was 1-47 where one cycle equals 28 days on bevaciumab every 2 week schedule and 42 days on bevacizumab every 3 weeks. Longest time any patient was on treatment was 5 years. Data that has been collected in the database is reported here. There is still some data entry of other adverse events for a few patient being completed and this Section will be updated accordingly when all data is entered and available for reporting (if applicable).
Nervous system disorders Hemorrhage - CNS	2.0% 1/50 • Adverse events were collected from the time of treatment initiation until 30 days post treatment discontinuation for all patients. Range of cycles of treatment completed by patients was 1-47 where one cycle equals 28 days on bevaciumab every 2 week schedule and 42 days on bevacizumab every 3 weeks. Longest time any patient was on treatment was 5 years. Data that has been collected in the database is reported here. There is still some data entry of other adverse events for a few patient being completed and this Section will be updated accordingly when all data is entered and available for reporting (if applicable).
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Disease progression	2.0% 1/50 • Adverse events were collected from the time of treatment initiation until 30 days post treatment discontinuation for all patients. Range of cycles of treatment completed by patients was 1-47 where one cycle equals 28 days on bevaciumab every 2 week schedule and 42 days on bevacizumab every 3 weeks. Longest time any patient was on treatment was 5 years. Data that has been collected in the database is reported here. There is still some data entry of other adverse events for a few patient being completed and this Section will be updated accordingly when all data is entered and available for reporting (if applicable).
Gastrointestinal disorders Dysphasia	2.0% 1/50 • Adverse events were collected from the time of treatment initiation until 30 days post treatment discontinuation for all patients. Range of cycles of treatment completed by patients was 1-47 where one cycle equals 28 days on bevaciumab every 2 week schedule and 42 days on bevacizumab every 3 weeks. Longest time any patient was on treatment was 5 years. Data that has been collected in the database is reported here. There is still some data entry of other adverse events for a few patient being completed and this Section will be updated accordingly when all data is entered and available for reporting (if applicable).

Other adverse events

Measure	Treatment With Bevacizumab n=50 participants at risk Patients receive bevacizumab IV over 30-90 minutes every 2 weeks for 6 months (1 cycle = 28 days with two doses of bevacizumab). Patients may then receive bevacizumab IV every 3 weeks for up to 12 months (1 cycle = 42 days) or stay on the 2 week cycle at the discretion of the treating physician. Treatment continues in the absence of disease progression or unacceptable toxicity. After 12 months of treatment patients may continue on bevacizumab at the discretion of their treating physician. bevacizumab: Given IV
Blood and lymphatic system disorders Anemia	6.0% 3/50 • Adverse events were collected from the time of treatment initiation until 30 days post treatment discontinuation for all patients. Range of cycles of treatment completed by patients was 1-47 where one cycle equals 28 days on bevaciumab every 2 week schedule and 42 days on bevacizumab every 3 weeks. Longest time any patient was on treatment was 5 years. Data that has been collected in the database is reported here. There is still some data entry of other adverse events for a few patient being completed and this Section will be updated accordingly when all data is entered and available for reporting (if applicable).
Cardiac disorders Auditory/ear NOS	4.0% 2/50 • Adverse events were collected from the time of treatment initiation until 30 days post treatment discontinuation for all patients. Range of cycles of treatment completed by patients was 1-47 where one cycle equals 28 days on bevaciumab every 2 week schedule and 42 days on bevacizumab every 3 weeks. Longest time any patient was on treatment was 5 years. Data that has been collected in the database is reported here. There is still some data entry of other adverse events for a few patient being completed and this Section will be updated accordingly when all data is entered and available for reporting (if applicable).
Ear and labyrinth disorders Tinnitus	4.0% 2/50 • Adverse events were collected from the time of treatment initiation until 30 days post treatment discontinuation for all patients. Range of cycles of treatment completed by patients was 1-47 where one cycle equals 28 days on bevaciumab every 2 week schedule and 42 days on bevacizumab every 3 weeks. Longest time any patient was on treatment was 5 years. Data that has been collected in the database is reported here. There is still some data entry of other adverse events for a few patient being completed and this Section will be updated accordingly when all data is entered and available for reporting (if applicable).
Ear and labyrinth disorders heaing impaired	4.0% 2/50 • Adverse events were collected from the time of treatment initiation until 30 days post treatment discontinuation for all patients. Range of cycles of treatment completed by patients was 1-47 where one cycle equals 28 days on bevaciumab every 2 week schedule and 42 days on bevacizumab every 3 weeks. Longest time any patient was on treatment was 5 years. Data that has been collected in the database is reported here. There is still some data entry of other adverse events for a few patient being completed and this Section will be updated accordingly when all data is entered and available for reporting (if applicable).
Eye disorders Blurred vision	4.0% 2/50 • Adverse events were collected from the time of treatment initiation until 30 days post treatment discontinuation for all patients. Range of cycles of treatment completed by patients was 1-47 where one cycle equals 28 days on bevaciumab every 2 week schedule and 42 days on bevacizumab every 3 weeks. Longest time any patient was on treatment was 5 years. Data that has been collected in the database is reported here. There is still some data entry of other adverse events for a few patient being completed and this Section will be updated accordingly when all data is entered and available for reporting (if applicable).
Eye disorders Ophthalmoplegia/diplopia (double vision)	6.0% 3/50 • Adverse events were collected from the time of treatment initiation until 30 days post treatment discontinuation for all patients. Range of cycles of treatment completed by patients was 1-47 where one cycle equals 28 days on bevaciumab every 2 week schedule and 42 days on bevacizumab every 3 weeks. Longest time any patient was on treatment was 5 years. Data that has been collected in the database is reported here. There is still some data entry of other adverse events for a few patient being completed and this Section will be updated accordingly when all data is entered and available for reporting (if applicable).
Eye disorders ocular vivsual other	4.0% 2/50 • Adverse events were collected from the time of treatment initiation until 30 days post treatment discontinuation for all patients. Range of cycles of treatment completed by patients was 1-47 where one cycle equals 28 days on bevaciumab every 2 week schedule and 42 days on bevacizumab every 3 weeks. Longest time any patient was on treatment was 5 years. Data that has been collected in the database is reported here. There is still some data entry of other adverse events for a few patient being completed and this Section will be updated accordingly when all data is entered and available for reporting (if applicable).
Eye disorders cataract	4.0% 2/50 • Adverse events were collected from the time of treatment initiation until 30 days post treatment discontinuation for all patients. Range of cycles of treatment completed by patients was 1-47 where one cycle equals 28 days on bevaciumab every 2 week schedule and 42 days on bevacizumab every 3 weeks. Longest time any patient was on treatment was 5 years. Data that has been collected in the database is reported here. There is still some data entry of other adverse events for a few patient being completed and this Section will be updated accordingly when all data is entered and available for reporting (if applicable).
Gastrointestinal disorders Constipation	16.0% 8/50 • Adverse events were collected from the time of treatment initiation until 30 days post treatment discontinuation for all patients. Range of cycles of treatment completed by patients was 1-47 where one cycle equals 28 days on bevaciumab every 2 week schedule and 42 days on bevacizumab every 3 weeks. Longest time any patient was on treatment was 5 years. Data that has been collected in the database is reported here. There is still some data entry of other adverse events for a few patient being completed and this Section will be updated accordingly when all data is entered and available for reporting (if applicable).
Gastrointestinal disorders Gastrointestinal disorders - Diarrhea	20.0% 10/50 • Adverse events were collected from the time of treatment initiation until 30 days post treatment discontinuation for all patients. Range of cycles of treatment completed by patients was 1-47 where one cycle equals 28 days on bevaciumab every 2 week schedule and 42 days on bevacizumab every 3 weeks. Longest time any patient was on treatment was 5 years. Data that has been collected in the database is reported here. There is still some data entry of other adverse events for a few patient being completed and this Section will be updated accordingly when all data is entered and available for reporting (if applicable).
Gastrointestinal disorders Gastrointestinal disorders - Dyspepsia	4.0% 2/50 • Adverse events were collected from the time of treatment initiation until 30 days post treatment discontinuation for all patients. Range of cycles of treatment completed by patients was 1-47 where one cycle equals 28 days on bevaciumab every 2 week schedule and 42 days on bevacizumab every 3 weeks. Longest time any patient was on treatment was 5 years. Data that has been collected in the database is reported here. There is still some data entry of other adverse events for a few patient being completed and this Section will be updated accordingly when all data is entered and available for reporting (if applicable).
Gastrointestinal disorders Gastritis	8.0% 4/50 • Adverse events were collected from the time of treatment initiation until 30 days post treatment discontinuation for all patients. Range of cycles of treatment completed by patients was 1-47 where one cycle equals 28 days on bevaciumab every 2 week schedule and 42 days on bevacizumab every 3 weeks. Longest time any patient was on treatment was 5 years. Data that has been collected in the database is reported here. There is still some data entry of other adverse events for a few patient being completed and this Section will be updated accordingly when all data is entered and available for reporting (if applicable).
Gastrointestinal disorders Gastrointestinal disorders - Nausea	32.0% 16/50 • Adverse events were collected from the time of treatment initiation until 30 days post treatment discontinuation for all patients. Range of cycles of treatment completed by patients was 1-47 where one cycle equals 28 days on bevaciumab every 2 week schedule and 42 days on bevacizumab every 3 weeks. Longest time any patient was on treatment was 5 years. Data that has been collected in the database is reported here. There is still some data entry of other adverse events for a few patient being completed and this Section will be updated accordingly when all data is entered and available for reporting (if applicable).
Gastrointestinal disorders Hemorrhage - oral cavity	4.0% 2/50 • Adverse events were collected from the time of treatment initiation until 30 days post treatment discontinuation for all patients. Range of cycles of treatment completed by patients was 1-47 where one cycle equals 28 days on bevaciumab every 2 week schedule and 42 days on bevacizumab every 3 weeks. Longest time any patient was on treatment was 5 years. Data that has been collected in the database is reported here. There is still some data entry of other adverse events for a few patient being completed and this Section will be updated accordingly when all data is entered and available for reporting (if applicable).
Gastrointestinal disorders Hemorrhoids	4.0% 2/50 • Adverse events were collected from the time of treatment initiation until 30 days post treatment discontinuation for all patients. Range of cycles of treatment completed by patients was 1-47 where one cycle equals 28 days on bevaciumab every 2 week schedule and 42 days on bevacizumab every 3 weeks. Longest time any patient was on treatment was 5 years. Data that has been collected in the database is reported here. There is still some data entry of other adverse events for a few patient being completed and this Section will be updated accordingly when all data is entered and available for reporting (if applicable).
Gastrointestinal disorders Gastrointestinal disorders - dysphagia	4.0% 2/50 • Adverse events were collected from the time of treatment initiation until 30 days post treatment discontinuation for all patients. Range of cycles of treatment completed by patients was 1-47 where one cycle equals 28 days on bevaciumab every 2 week schedule and 42 days on bevacizumab every 3 weeks. Longest time any patient was on treatment was 5 years. Data that has been collected in the database is reported here. There is still some data entry of other adverse events for a few patient being completed and this Section will be updated accordingly when all data is entered and available for reporting (if applicable).
General disorders General disorders and administration site conditions - Edema limbs	12.0% 6/50 • Adverse events were collected from the time of treatment initiation until 30 days post treatment discontinuation for all patients. Range of cycles of treatment completed by patients was 1-47 where one cycle equals 28 days on bevaciumab every 2 week schedule and 42 days on bevacizumab every 3 weeks. Longest time any patient was on treatment was 5 years. Data that has been collected in the database is reported here. There is still some data entry of other adverse events for a few patient being completed and this Section will be updated accordingly when all data is entered and available for reporting (if applicable).
General disorders General disorders and administration site conditions - Fatigue	42.0% 21/50 • Adverse events were collected from the time of treatment initiation until 30 days post treatment discontinuation for all patients. Range of cycles of treatment completed by patients was 1-47 where one cycle equals 28 days on bevaciumab every 2 week schedule and 42 days on bevacizumab every 3 weeks. Longest time any patient was on treatment was 5 years. Data that has been collected in the database is reported here. There is still some data entry of other adverse events for a few patient being completed and this Section will be updated accordingly when all data is entered and available for reporting (if applicable).
General disorders General disorders and administration site conditions - Gait disturbance	8.0% 4/50 • Adverse events were collected from the time of treatment initiation until 30 days post treatment discontinuation for all patients. Range of cycles of treatment completed by patients was 1-47 where one cycle equals 28 days on bevaciumab every 2 week schedule and 42 days on bevacizumab every 3 weeks. Longest time any patient was on treatment was 5 years. Data that has been collected in the database is reported here. There is still some data entry of other adverse events for a few patient being completed and this Section will be updated accordingly when all data is entered and available for reporting (if applicable).
General disorders General disorders and administration site conditions - pain	36.0% 18/50 • Adverse events were collected from the time of treatment initiation until 30 days post treatment discontinuation for all patients. Range of cycles of treatment completed by patients was 1-47 where one cycle equals 28 days on bevaciumab every 2 week schedule and 42 days on bevacizumab every 3 weeks. Longest time any patient was on treatment was 5 years. Data that has been collected in the database is reported here. There is still some data entry of other adverse events for a few patient being completed and this Section will be updated accordingly when all data is entered and available for reporting (if applicable).
Infections and infestations ear infection	4.0% 2/50 • Adverse events were collected from the time of treatment initiation until 30 days post treatment discontinuation for all patients. Range of cycles of treatment completed by patients was 1-47 where one cycle equals 28 days on bevaciumab every 2 week schedule and 42 days on bevacizumab every 3 weeks. Longest time any patient was on treatment was 5 years. Data that has been collected in the database is reported here. There is still some data entry of other adverse events for a few patient being completed and this Section will be updated accordingly when all data is entered and available for reporting (if applicable).
Infections and infestations Infections and infestations - other, specify	4.0% 2/50 • Adverse events were collected from the time of treatment initiation until 30 days post treatment discontinuation for all patients. Range of cycles of treatment completed by patients was 1-47 where one cycle equals 28 days on bevaciumab every 2 week schedule and 42 days on bevacizumab every 3 weeks. Longest time any patient was on treatment was 5 years. Data that has been collected in the database is reported here. There is still some data entry of other adverse events for a few patient being completed and this Section will be updated accordingly when all data is entered and available for reporting (if applicable).
Infections and infestations Infections and infestations -Urinary tract infection	6.0% 3/50 • Adverse events were collected from the time of treatment initiation until 30 days post treatment discontinuation for all patients. Range of cycles of treatment completed by patients was 1-47 where one cycle equals 28 days on bevaciumab every 2 week schedule and 42 days on bevacizumab every 3 weeks. Longest time any patient was on treatment was 5 years. Data that has been collected in the database is reported here. There is still some data entry of other adverse events for a few patient being completed and this Section will be updated accordingly when all data is entered and available for reporting (if applicable).
Investigations Investigations - Alanine aminotransferase increased	14.0% 7/50 • Adverse events were collected from the time of treatment initiation until 30 days post treatment discontinuation for all patients. Range of cycles of treatment completed by patients was 1-47 where one cycle equals 28 days on bevaciumab every 2 week schedule and 42 days on bevacizumab every 3 weeks. Longest time any patient was on treatment was 5 years. Data that has been collected in the database is reported here. There is still some data entry of other adverse events for a few patient being completed and this Section will be updated accordingly when all data is entered and available for reporting (if applicable).
Investigations Investigations - Alkaline phosphatase increased	8.0% 4/50 • Adverse events were collected from the time of treatment initiation until 30 days post treatment discontinuation for all patients. Range of cycles of treatment completed by patients was 1-47 where one cycle equals 28 days on bevaciumab every 2 week schedule and 42 days on bevacizumab every 3 weeks. Longest time any patient was on treatment was 5 years. Data that has been collected in the database is reported here. There is still some data entry of other adverse events for a few patient being completed and this Section will be updated accordingly when all data is entered and available for reporting (if applicable).
Investigations Investigations - Aspartate aminotransferase increased	20.0% 10/50 • Adverse events were collected from the time of treatment initiation until 30 days post treatment discontinuation for all patients. Range of cycles of treatment completed by patients was 1-47 where one cycle equals 28 days on bevaciumab every 2 week schedule and 42 days on bevacizumab every 3 weeks. Longest time any patient was on treatment was 5 years. Data that has been collected in the database is reported here. There is still some data entry of other adverse events for a few patient being completed and this Section will be updated accordingly when all data is entered and available for reporting (if applicable).
Investigations Investigations - Blood bilirubin increased	4.0% 2/50 • Adverse events were collected from the time of treatment initiation until 30 days post treatment discontinuation for all patients. Range of cycles of treatment completed by patients was 1-47 where one cycle equals 28 days on bevaciumab every 2 week schedule and 42 days on bevacizumab every 3 weeks. Longest time any patient was on treatment was 5 years. Data that has been collected in the database is reported here. There is still some data entry of other adverse events for a few patient being completed and this Section will be updated accordingly when all data is entered and available for reporting (if applicable).
Investigations Investigations - Creatinine increased	6.0% 3/50 • Adverse events were collected from the time of treatment initiation until 30 days post treatment discontinuation for all patients. Range of cycles of treatment completed by patients was 1-47 where one cycle equals 28 days on bevaciumab every 2 week schedule and 42 days on bevacizumab every 3 weeks. Longest time any patient was on treatment was 5 years. Data that has been collected in the database is reported here. There is still some data entry of other adverse events for a few patient being completed and this Section will be updated accordingly when all data is entered and available for reporting (if applicable).
Investigations Investigations - Bicarbonate Serum Low	4.0% 2/50 • Adverse events were collected from the time of treatment initiation until 30 days post treatment discontinuation for all patients. Range of cycles of treatment completed by patients was 1-47 where one cycle equals 28 days on bevaciumab every 2 week schedule and 42 days on bevacizumab every 3 weeks. Longest time any patient was on treatment was 5 years. Data that has been collected in the database is reported here. There is still some data entry of other adverse events for a few patient being completed and this Section will be updated accordingly when all data is entered and available for reporting (if applicable).
Investigations Investigations - Lymphocyte count decreased	16.0% 8/50 • Adverse events were collected from the time of treatment initiation until 30 days post treatment discontinuation for all patients. Range of cycles of treatment completed by patients was 1-47 where one cycle equals 28 days on bevaciumab every 2 week schedule and 42 days on bevacizumab every 3 weeks. Longest time any patient was on treatment was 5 years. Data that has been collected in the database is reported here. There is still some data entry of other adverse events for a few patient being completed and this Section will be updated accordingly when all data is entered and available for reporting (if applicable).
Investigations Investigations - Platelet count decreased	12.0% 6/50 • Adverse events were collected from the time of treatment initiation until 30 days post treatment discontinuation for all patients. Range of cycles of treatment completed by patients was 1-47 where one cycle equals 28 days on bevaciumab every 2 week schedule and 42 days on bevacizumab every 3 weeks. Longest time any patient was on treatment was 5 years. Data that has been collected in the database is reported here. There is still some data entry of other adverse events for a few patient being completed and this Section will be updated accordingly when all data is entered and available for reporting (if applicable).
Investigations Neutrophil count decrease	6.0% 3/50 • Adverse events were collected from the time of treatment initiation until 30 days post treatment discontinuation for all patients. Range of cycles of treatment completed by patients was 1-47 where one cycle equals 28 days on bevaciumab every 2 week schedule and 42 days on bevacizumab every 3 weeks. Longest time any patient was on treatment was 5 years. Data that has been collected in the database is reported here. There is still some data entry of other adverse events for a few patient being completed and this Section will be updated accordingly when all data is entered and available for reporting (if applicable).
Investigations Investigations - Weight loss	8.0% 4/50 • Adverse events were collected from the time of treatment initiation until 30 days post treatment discontinuation for all patients. Range of cycles of treatment completed by patients was 1-47 where one cycle equals 28 days on bevaciumab every 2 week schedule and 42 days on bevacizumab every 3 weeks. Longest time any patient was on treatment was 5 years. Data that has been collected in the database is reported here. There is still some data entry of other adverse events for a few patient being completed and this Section will be updated accordingly when all data is entered and available for reporting (if applicable).
Investigations Investigations - White blood cell decreased	16.0% 8/50 • Adverse events were collected from the time of treatment initiation until 30 days post treatment discontinuation for all patients. Range of cycles of treatment completed by patients was 1-47 where one cycle equals 28 days on bevaciumab every 2 week schedule and 42 days on bevacizumab every 3 weeks. Longest time any patient was on treatment was 5 years. Data that has been collected in the database is reported here. There is still some data entry of other adverse events for a few patient being completed and this Section will be updated accordingly when all data is entered and available for reporting (if applicable).
Injury, poisoning and procedural complications Bruising	6.0% 3/50 • Adverse events were collected from the time of treatment initiation until 30 days post treatment discontinuation for all patients. Range of cycles of treatment completed by patients was 1-47 where one cycle equals 28 days on bevaciumab every 2 week schedule and 42 days on bevacizumab every 3 weeks. Longest time any patient was on treatment was 5 years. Data that has been collected in the database is reported here. There is still some data entry of other adverse events for a few patient being completed and this Section will be updated accordingly when all data is entered and available for reporting (if applicable).
Metabolism and nutrition disorders Dehydration	4.0% 2/50 • Adverse events were collected from the time of treatment initiation until 30 days post treatment discontinuation for all patients. Range of cycles of treatment completed by patients was 1-47 where one cycle equals 28 days on bevaciumab every 2 week schedule and 42 days on bevacizumab every 3 weeks. Longest time any patient was on treatment was 5 years. Data that has been collected in the database is reported here. There is still some data entry of other adverse events for a few patient being completed and this Section will be updated accordingly when all data is entered and available for reporting (if applicable).
Metabolism and nutrition disorders Hypercalcemia	6.0% 3/50 • Adverse events were collected from the time of treatment initiation until 30 days post treatment discontinuation for all patients. Range of cycles of treatment completed by patients was 1-47 where one cycle equals 28 days on bevaciumab every 2 week schedule and 42 days on bevacizumab every 3 weeks. Longest time any patient was on treatment was 5 years. Data that has been collected in the database is reported here. There is still some data entry of other adverse events for a few patient being completed and this Section will be updated accordingly when all data is entered and available for reporting (if applicable).
Metabolism and nutrition disorders Hyperglycemia	38.0% 19/50 • Adverse events were collected from the time of treatment initiation until 30 days post treatment discontinuation for all patients. Range of cycles of treatment completed by patients was 1-47 where one cycle equals 28 days on bevaciumab every 2 week schedule and 42 days on bevacizumab every 3 weeks. Longest time any patient was on treatment was 5 years. Data that has been collected in the database is reported here. There is still some data entry of other adverse events for a few patient being completed and this Section will be updated accordingly when all data is entered and available for reporting (if applicable).
Metabolism and nutrition disorders Hyperkalemia	6.0% 3/50 • Adverse events were collected from the time of treatment initiation until 30 days post treatment discontinuation for all patients. Range of cycles of treatment completed by patients was 1-47 where one cycle equals 28 days on bevaciumab every 2 week schedule and 42 days on bevacizumab every 3 weeks. Longest time any patient was on treatment was 5 years. Data that has been collected in the database is reported here. There is still some data entry of other adverse events for a few patient being completed and this Section will be updated accordingly when all data is entered and available for reporting (if applicable).
Metabolism and nutrition disorders Hypernatremia	6.0% 3/50 • Adverse events were collected from the time of treatment initiation until 30 days post treatment discontinuation for all patients. Range of cycles of treatment completed by patients was 1-47 where one cycle equals 28 days on bevaciumab every 2 week schedule and 42 days on bevacizumab every 3 weeks. Longest time any patient was on treatment was 5 years. Data that has been collected in the database is reported here. There is still some data entry of other adverse events for a few patient being completed and this Section will be updated accordingly when all data is entered and available for reporting (if applicable).
Metabolism and nutrition disorders Hypoalbuminemia	28.0% 14/50 • Adverse events were collected from the time of treatment initiation until 30 days post treatment discontinuation for all patients. Range of cycles of treatment completed by patients was 1-47 where one cycle equals 28 days on bevaciumab every 2 week schedule and 42 days on bevacizumab every 3 weeks. Longest time any patient was on treatment was 5 years. Data that has been collected in the database is reported here. There is still some data entry of other adverse events for a few patient being completed and this Section will be updated accordingly when all data is entered and available for reporting (if applicable).
Metabolism and nutrition disorders Hypocalcemia	12.0% 6/50 • Adverse events were collected from the time of treatment initiation until 30 days post treatment discontinuation for all patients. Range of cycles of treatment completed by patients was 1-47 where one cycle equals 28 days on bevaciumab every 2 week schedule and 42 days on bevacizumab every 3 weeks. Longest time any patient was on treatment was 5 years. Data that has been collected in the database is reported here. There is still some data entry of other adverse events for a few patient being completed and this Section will be updated accordingly when all data is entered and available for reporting (if applicable).
Metabolism and nutrition disorders Hypoglycemia	12.0% 6/50 • Adverse events were collected from the time of treatment initiation until 30 days post treatment discontinuation for all patients. Range of cycles of treatment completed by patients was 1-47 where one cycle equals 28 days on bevaciumab every 2 week schedule and 42 days on bevacizumab every 3 weeks. Longest time any patient was on treatment was 5 years. Data that has been collected in the database is reported here. There is still some data entry of other adverse events for a few patient being completed and this Section will be updated accordingly when all data is entered and available for reporting (if applicable).
Metabolism and nutrition disorders Hypokalemia	10.0% 5/50 • Adverse events were collected from the time of treatment initiation until 30 days post treatment discontinuation for all patients. Range of cycles of treatment completed by patients was 1-47 where one cycle equals 28 days on bevaciumab every 2 week schedule and 42 days on bevacizumab every 3 weeks. Longest time any patient was on treatment was 5 years. Data that has been collected in the database is reported here. There is still some data entry of other adverse events for a few patient being completed and this Section will be updated accordingly when all data is entered and available for reporting (if applicable).
Metabolism and nutrition disorders Hypomagnesmia	4.0% 2/50 • Adverse events were collected from the time of treatment initiation until 30 days post treatment discontinuation for all patients. Range of cycles of treatment completed by patients was 1-47 where one cycle equals 28 days on bevaciumab every 2 week schedule and 42 days on bevacizumab every 3 weeks. Longest time any patient was on treatment was 5 years. Data that has been collected in the database is reported here. There is still some data entry of other adverse events for a few patient being completed and this Section will be updated accordingly when all data is entered and available for reporting (if applicable).
Metabolism and nutrition disorders Hyponatremia	4.0% 2/50 • Adverse events were collected from the time of treatment initiation until 30 days post treatment discontinuation for all patients. Range of cycles of treatment completed by patients was 1-47 where one cycle equals 28 days on bevaciumab every 2 week schedule and 42 days on bevacizumab every 3 weeks. Longest time any patient was on treatment was 5 years. Data that has been collected in the database is reported here. There is still some data entry of other adverse events for a few patient being completed and this Section will be updated accordingly when all data is entered and available for reporting (if applicable).
Metabolism and nutrition disorders Hypophosphatemia	8.0% 4/50 • Adverse events were collected from the time of treatment initiation until 30 days post treatment discontinuation for all patients. Range of cycles of treatment completed by patients was 1-47 where one cycle equals 28 days on bevaciumab every 2 week schedule and 42 days on bevacizumab every 3 weeks. Longest time any patient was on treatment was 5 years. Data that has been collected in the database is reported here. There is still some data entry of other adverse events for a few patient being completed and this Section will be updated accordingly when all data is entered and available for reporting (if applicable).
Metabolism and nutrition disorders BUN elevated	4.0% 2/50 • Adverse events were collected from the time of treatment initiation until 30 days post treatment discontinuation for all patients. Range of cycles of treatment completed by patients was 1-47 where one cycle equals 28 days on bevaciumab every 2 week schedule and 42 days on bevacizumab every 3 weeks. Longest time any patient was on treatment was 5 years. Data that has been collected in the database is reported here. There is still some data entry of other adverse events for a few patient being completed and this Section will be updated accordingly when all data is entered and available for reporting (if applicable).
Metabolism and nutrition disorders Urine - WBCs detected	4.0% 2/50 • Adverse events were collected from the time of treatment initiation until 30 days post treatment discontinuation for all patients. Range of cycles of treatment completed by patients was 1-47 where one cycle equals 28 days on bevaciumab every 2 week schedule and 42 days on bevacizumab every 3 weeks. Longest time any patient was on treatment was 5 years. Data that has been collected in the database is reported here. There is still some data entry of other adverse events for a few patient being completed and this Section will be updated accordingly when all data is entered and available for reporting (if applicable).
Metabolism and nutrition disorders Urine Casts detected	6.0% 3/50 • Adverse events were collected from the time of treatment initiation until 30 days post treatment discontinuation for all patients. Range of cycles of treatment completed by patients was 1-47 where one cycle equals 28 days on bevaciumab every 2 week schedule and 42 days on bevacizumab every 3 weeks. Longest time any patient was on treatment was 5 years. Data that has been collected in the database is reported here. There is still some data entry of other adverse events for a few patient being completed and this Section will be updated accordingly when all data is entered and available for reporting (if applicable).
Metabolism and nutrition disorders Chloride Elevated	4.0% 2/50 • Adverse events were collected from the time of treatment initiation until 30 days post treatment discontinuation for all patients. Range of cycles of treatment completed by patients was 1-47 where one cycle equals 28 days on bevaciumab every 2 week schedule and 42 days on bevacizumab every 3 weeks. Longest time any patient was on treatment was 5 years. Data that has been collected in the database is reported here. There is still some data entry of other adverse events for a few patient being completed and this Section will be updated accordingly when all data is entered and available for reporting (if applicable).
Musculoskeletal and connective tissue disorders Arthritis	4.0% 2/50 • Adverse events were collected from the time of treatment initiation until 30 days post treatment discontinuation for all patients. Range of cycles of treatment completed by patients was 1-47 where one cycle equals 28 days on bevaciumab every 2 week schedule and 42 days on bevacizumab every 3 weeks. Longest time any patient was on treatment was 5 years. Data that has been collected in the database is reported here. There is still some data entry of other adverse events for a few patient being completed and this Section will be updated accordingly when all data is entered and available for reporting (if applicable).
General disorders Teeth pain	4.0% 2/50 • Adverse events were collected from the time of treatment initiation until 30 days post treatment discontinuation for all patients. Range of cycles of treatment completed by patients was 1-47 where one cycle equals 28 days on bevaciumab every 2 week schedule and 42 days on bevacizumab every 3 weeks. Longest time any patient was on treatment was 5 years. Data that has been collected in the database is reported here. There is still some data entry of other adverse events for a few patient being completed and this Section will be updated accordingly when all data is entered and available for reporting (if applicable).
Musculoskeletal and connective tissue disorders extremity limb pain	4.0% 2/50 • Adverse events were collected from the time of treatment initiation until 30 days post treatment discontinuation for all patients. Range of cycles of treatment completed by patients was 1-47 where one cycle equals 28 days on bevaciumab every 2 week schedule and 42 days on bevacizumab every 3 weeks. Longest time any patient was on treatment was 5 years. Data that has been collected in the database is reported here. There is still some data entry of other adverse events for a few patient being completed and this Section will be updated accordingly when all data is entered and available for reporting (if applicable).
Musculoskeletal and connective tissue disorders Muscle weakness - extraocular	8.0% 4/50 • Adverse events were collected from the time of treatment initiation until 30 days post treatment discontinuation for all patients. Range of cycles of treatment completed by patients was 1-47 where one cycle equals 28 days on bevaciumab every 2 week schedule and 42 days on bevacizumab every 3 weeks. Longest time any patient was on treatment was 5 years. Data that has been collected in the database is reported here. There is still some data entry of other adverse events for a few patient being completed and this Section will be updated accordingly when all data is entered and available for reporting (if applicable).
Musculoskeletal and connective tissue disorders Muscle weakness - extremity lower	6.0% 3/50 • Adverse events were collected from the time of treatment initiation until 30 days post treatment discontinuation for all patients. Range of cycles of treatment completed by patients was 1-47 where one cycle equals 28 days on bevaciumab every 2 week schedule and 42 days on bevacizumab every 3 weeks. Longest time any patient was on treatment was 5 years. Data that has been collected in the database is reported here. There is still some data entry of other adverse events for a few patient being completed and this Section will be updated accordingly when all data is entered and available for reporting (if applicable).
Musculoskeletal and connective tissue disorders Shoulder Pain	4.0% 2/50 • Adverse events were collected from the time of treatment initiation until 30 days post treatment discontinuation for all patients. Range of cycles of treatment completed by patients was 1-47 where one cycle equals 28 days on bevaciumab every 2 week schedule and 42 days on bevacizumab every 3 weeks. Longest time any patient was on treatment was 5 years. Data that has been collected in the database is reported here. There is still some data entry of other adverse events for a few patient being completed and this Section will be updated accordingly when all data is entered and available for reporting (if applicable).
Musculoskeletal and connective tissue disorders Spasicity	4.0% 2/50 • Adverse events were collected from the time of treatment initiation until 30 days post treatment discontinuation for all patients. Range of cycles of treatment completed by patients was 1-47 where one cycle equals 28 days on bevaciumab every 2 week schedule and 42 days on bevacizumab every 3 weeks. Longest time any patient was on treatment was 5 years. Data that has been collected in the database is reported here. There is still some data entry of other adverse events for a few patient being completed and this Section will be updated accordingly when all data is entered and available for reporting (if applicable).
Musculoskeletal and connective tissue disorders Neck pain	6.0% 3/50 • Adverse events were collected from the time of treatment initiation until 30 days post treatment discontinuation for all patients. Range of cycles of treatment completed by patients was 1-47 where one cycle equals 28 days on bevaciumab every 2 week schedule and 42 days on bevacizumab every 3 weeks. Longest time any patient was on treatment was 5 years. Data that has been collected in the database is reported here. There is still some data entry of other adverse events for a few patient being completed and this Section will be updated accordingly when all data is entered and available for reporting (if applicable).
Nervous system disorders Cognitive Disturbance	4.0% 2/50 • Adverse events were collected from the time of treatment initiation until 30 days post treatment discontinuation for all patients. Range of cycles of treatment completed by patients was 1-47 where one cycle equals 28 days on bevaciumab every 2 week schedule and 42 days on bevacizumab every 3 weeks. Longest time any patient was on treatment was 5 years. Data that has been collected in the database is reported here. There is still some data entry of other adverse events for a few patient being completed and this Section will be updated accordingly when all data is entered and available for reporting (if applicable).
Nervous system disorders Confusion	8.0% 4/50 • Adverse events were collected from the time of treatment initiation until 30 days post treatment discontinuation for all patients. Range of cycles of treatment completed by patients was 1-47 where one cycle equals 28 days on bevaciumab every 2 week schedule and 42 days on bevacizumab every 3 weeks. Longest time any patient was on treatment was 5 years. Data that has been collected in the database is reported here. There is still some data entry of other adverse events for a few patient being completed and this Section will be updated accordingly when all data is entered and available for reporting (if applicable).
Nervous system disorders Dizziness	14.0% 7/50 • Adverse events were collected from the time of treatment initiation until 30 days post treatment discontinuation for all patients. Range of cycles of treatment completed by patients was 1-47 where one cycle equals 28 days on bevaciumab every 2 week schedule and 42 days on bevacizumab every 3 weeks. Longest time any patient was on treatment was 5 years. Data that has been collected in the database is reported here. There is still some data entry of other adverse events for a few patient being completed and this Section will be updated accordingly when all data is entered and available for reporting (if applicable).
Nervous system disorders Dysphasia	6.0% 3/50 • Adverse events were collected from the time of treatment initiation until 30 days post treatment discontinuation for all patients. Range of cycles of treatment completed by patients was 1-47 where one cycle equals 28 days on bevaciumab every 2 week schedule and 42 days on bevacizumab every 3 weeks. Longest time any patient was on treatment was 5 years. Data that has been collected in the database is reported here. There is still some data entry of other adverse events for a few patient being completed and this Section will be updated accordingly when all data is entered and available for reporting (if applicable).
Nervous system disorders dysarthria	14.0% 7/50 • Adverse events were collected from the time of treatment initiation until 30 days post treatment discontinuation for all patients. Range of cycles of treatment completed by patients was 1-47 where one cycle equals 28 days on bevaciumab every 2 week schedule and 42 days on bevacizumab every 3 weeks. Longest time any patient was on treatment was 5 years. Data that has been collected in the database is reported here. There is still some data entry of other adverse events for a few patient being completed and this Section will be updated accordingly when all data is entered and available for reporting (if applicable).
Nervous system disorders Extrapyramidal disorder	4.0% 2/50 • Adverse events were collected from the time of treatment initiation until 30 days post treatment discontinuation for all patients. Range of cycles of treatment completed by patients was 1-47 where one cycle equals 28 days on bevaciumab every 2 week schedule and 42 days on bevacizumab every 3 weeks. Longest time any patient was on treatment was 5 years. Data that has been collected in the database is reported here. There is still some data entry of other adverse events for a few patient being completed and this Section will be updated accordingly when all data is entered and available for reporting (if applicable).
Nervous system disorders Headaches	42.0% 21/50 • Adverse events were collected from the time of treatment initiation until 30 days post treatment discontinuation for all patients. Range of cycles of treatment completed by patients was 1-47 where one cycle equals 28 days on bevaciumab every 2 week schedule and 42 days on bevacizumab every 3 weeks. Longest time any patient was on treatment was 5 years. Data that has been collected in the database is reported here. There is still some data entry of other adverse events for a few patient being completed and this Section will be updated accordingly when all data is entered and available for reporting (if applicable).
Nervous system disorders Memory impairment	10.0% 5/50 • Adverse events were collected from the time of treatment initiation until 30 days post treatment discontinuation for all patients. Range of cycles of treatment completed by patients was 1-47 where one cycle equals 28 days on bevaciumab every 2 week schedule and 42 days on bevacizumab every 3 weeks. Longest time any patient was on treatment was 5 years. Data that has been collected in the database is reported here. There is still some data entry of other adverse events for a few patient being completed and this Section will be updated accordingly when all data is entered and available for reporting (if applicable).
Nervous system disorders Seizure	12.0% 6/50 • Adverse events were collected from the time of treatment initiation until 30 days post treatment discontinuation for all patients. Range of cycles of treatment completed by patients was 1-47 where one cycle equals 28 days on bevaciumab every 2 week schedule and 42 days on bevacizumab every 3 weeks. Longest time any patient was on treatment was 5 years. Data that has been collected in the database is reported here. There is still some data entry of other adverse events for a few patient being completed and this Section will be updated accordingly when all data is entered and available for reporting (if applicable).
Nervous system disorders Peripheral motor neuropathy	12.0% 6/50 • Adverse events were collected from the time of treatment initiation until 30 days post treatment discontinuation for all patients. Range of cycles of treatment completed by patients was 1-47 where one cycle equals 28 days on bevaciumab every 2 week schedule and 42 days on bevacizumab every 3 weeks. Longest time any patient was on treatment was 5 years. Data that has been collected in the database is reported here. There is still some data entry of other adverse events for a few patient being completed and this Section will be updated accordingly when all data is entered and available for reporting (if applicable).
Nervous system disorders Peripheral sensory neuropathy	10.0% 5/50 • Adverse events were collected from the time of treatment initiation until 30 days post treatment discontinuation for all patients. Range of cycles of treatment completed by patients was 1-47 where one cycle equals 28 days on bevaciumab every 2 week schedule and 42 days on bevacizumab every 3 weeks. Longest time any patient was on treatment was 5 years. Data that has been collected in the database is reported here. There is still some data entry of other adverse events for a few patient being completed and this Section will be updated accordingly when all data is entered and available for reporting (if applicable).
Nervous system disorders somnolence	4.0% 2/50 • Adverse events were collected from the time of treatment initiation until 30 days post treatment discontinuation for all patients. Range of cycles of treatment completed by patients was 1-47 where one cycle equals 28 days on bevaciumab every 2 week schedule and 42 days on bevacizumab every 3 weeks. Longest time any patient was on treatment was 5 years. Data that has been collected in the database is reported here. There is still some data entry of other adverse events for a few patient being completed and this Section will be updated accordingly when all data is entered and available for reporting (if applicable).
Nervous system disorders Tremor	4.0% 2/50 • Adverse events were collected from the time of treatment initiation until 30 days post treatment discontinuation for all patients. Range of cycles of treatment completed by patients was 1-47 where one cycle equals 28 days on bevaciumab every 2 week schedule and 42 days on bevacizumab every 3 weeks. Longest time any patient was on treatment was 5 years. Data that has been collected in the database is reported here. There is still some data entry of other adverse events for a few patient being completed and this Section will be updated accordingly when all data is entered and available for reporting (if applicable).
Nervous system disorders Agitation	4.0% 2/50 • Adverse events were collected from the time of treatment initiation until 30 days post treatment discontinuation for all patients. Range of cycles of treatment completed by patients was 1-47 where one cycle equals 28 days on bevaciumab every 2 week schedule and 42 days on bevacizumab every 3 weeks. Longest time any patient was on treatment was 5 years. Data that has been collected in the database is reported here. There is still some data entry of other adverse events for a few patient being completed and this Section will be updated accordingly when all data is entered and available for reporting (if applicable).
Psychiatric disorders Insomnia	14.0% 7/50 • Adverse events were collected from the time of treatment initiation until 30 days post treatment discontinuation for all patients. Range of cycles of treatment completed by patients was 1-47 where one cycle equals 28 days on bevaciumab every 2 week schedule and 42 days on bevacizumab every 3 weeks. Longest time any patient was on treatment was 5 years. Data that has been collected in the database is reported here. There is still some data entry of other adverse events for a few patient being completed and this Section will be updated accordingly when all data is entered and available for reporting (if applicable).
Psychiatric disorders Depression	6.0% 3/50 • Adverse events were collected from the time of treatment initiation until 30 days post treatment discontinuation for all patients. Range of cycles of treatment completed by patients was 1-47 where one cycle equals 28 days on bevaciumab every 2 week schedule and 42 days on bevacizumab every 3 weeks. Longest time any patient was on treatment was 5 years. Data that has been collected in the database is reported here. There is still some data entry of other adverse events for a few patient being completed and this Section will be updated accordingly when all data is entered and available for reporting (if applicable).
Renal and urinary disorders Urinary incontinence	6.0% 3/50 • Adverse events were collected from the time of treatment initiation until 30 days post treatment discontinuation for all patients. Range of cycles of treatment completed by patients was 1-47 where one cycle equals 28 days on bevaciumab every 2 week schedule and 42 days on bevacizumab every 3 weeks. Longest time any patient was on treatment was 5 years. Data that has been collected in the database is reported here. There is still some data entry of other adverse events for a few patient being completed and this Section will be updated accordingly when all data is entered and available for reporting (if applicable).
Renal and urinary disorders Urinary frequency	6.0% 3/50 • Adverse events were collected from the time of treatment initiation until 30 days post treatment discontinuation for all patients. Range of cycles of treatment completed by patients was 1-47 where one cycle equals 28 days on bevaciumab every 2 week schedule and 42 days on bevacizumab every 3 weeks. Longest time any patient was on treatment was 5 years. Data that has been collected in the database is reported here. There is still some data entry of other adverse events for a few patient being completed and this Section will be updated accordingly when all data is entered and available for reporting (if applicable).
Renal and urinary disorders Proteinuria	32.0% 16/50 • Adverse events were collected from the time of treatment initiation until 30 days post treatment discontinuation for all patients. Range of cycles of treatment completed by patients was 1-47 where one cycle equals 28 days on bevaciumab every 2 week schedule and 42 days on bevacizumab every 3 weeks. Longest time any patient was on treatment was 5 years. Data that has been collected in the database is reported here. There is still some data entry of other adverse events for a few patient being completed and this Section will be updated accordingly when all data is entered and available for reporting (if applicable).
Renal and urinary disorders renal/genitourinary - other	4.0% 2/50 • Adverse events were collected from the time of treatment initiation until 30 days post treatment discontinuation for all patients. Range of cycles of treatment completed by patients was 1-47 where one cycle equals 28 days on bevaciumab every 2 week schedule and 42 days on bevacizumab every 3 weeks. Longest time any patient was on treatment was 5 years. Data that has been collected in the database is reported here. There is still some data entry of other adverse events for a few patient being completed and this Section will be updated accordingly when all data is entered and available for reporting (if applicable).
Reproductive system and breast disorders irregular menstration	8.0% 4/50 • Adverse events were collected from the time of treatment initiation until 30 days post treatment discontinuation for all patients. Range of cycles of treatment completed by patients was 1-47 where one cycle equals 28 days on bevaciumab every 2 week schedule and 42 days on bevacizumab every 3 weeks. Longest time any patient was on treatment was 5 years. Data that has been collected in the database is reported here. There is still some data entry of other adverse events for a few patient being completed and this Section will be updated accordingly when all data is entered and available for reporting (if applicable).
Respiratory, thoracic and mediastinal disorders Cough	8.0% 4/50 • Adverse events were collected from the time of treatment initiation until 30 days post treatment discontinuation for all patients. Range of cycles of treatment completed by patients was 1-47 where one cycle equals 28 days on bevaciumab every 2 week schedule and 42 days on bevacizumab every 3 weeks. Longest time any patient was on treatment was 5 years. Data that has been collected in the database is reported here. There is still some data entry of other adverse events for a few patient being completed and this Section will be updated accordingly when all data is entered and available for reporting (if applicable).
Respiratory, thoracic and mediastinal disorders Nose bleed	22.0% 11/50 • Adverse events were collected from the time of treatment initiation until 30 days post treatment discontinuation for all patients. Range of cycles of treatment completed by patients was 1-47 where one cycle equals 28 days on bevaciumab every 2 week schedule and 42 days on bevacizumab every 3 weeks. Longest time any patient was on treatment was 5 years. Data that has been collected in the database is reported here. There is still some data entry of other adverse events for a few patient being completed and this Section will be updated accordingly when all data is entered and available for reporting (if applicable).
Respiratory, thoracic and mediastinal disorders Pulmonary/ upper respiratory - otheh	6.0% 3/50 • Adverse events were collected from the time of treatment initiation until 30 days post treatment discontinuation for all patients. Range of cycles of treatment completed by patients was 1-47 where one cycle equals 28 days on bevaciumab every 2 week schedule and 42 days on bevacizumab every 3 weeks. Longest time any patient was on treatment was 5 years. Data that has been collected in the database is reported here. There is still some data entry of other adverse events for a few patient being completed and this Section will be updated accordingly when all data is entered and available for reporting (if applicable).
Skin and subcutaneous tissue disorders Pruritus	4.0% 2/50 • Adverse events were collected from the time of treatment initiation until 30 days post treatment discontinuation for all patients. Range of cycles of treatment completed by patients was 1-47 where one cycle equals 28 days on bevaciumab every 2 week schedule and 42 days on bevacizumab every 3 weeks. Longest time any patient was on treatment was 5 years. Data that has been collected in the database is reported here. There is still some data entry of other adverse events for a few patient being completed and this Section will be updated accordingly when all data is entered and available for reporting (if applicable).
Skin and subcutaneous tissue disorders Rash acneiform	4.0% 2/50 • Adverse events were collected from the time of treatment initiation until 30 days post treatment discontinuation for all patients. Range of cycles of treatment completed by patients was 1-47 where one cycle equals 28 days on bevaciumab every 2 week schedule and 42 days on bevacizumab every 3 weeks. Longest time any patient was on treatment was 5 years. Data that has been collected in the database is reported here. There is still some data entry of other adverse events for a few patient being completed and this Section will be updated accordingly when all data is entered and available for reporting (if applicable).
Skin and subcutaneous tissue disorders Rash/desquamation	8.0% 4/50 • Adverse events were collected from the time of treatment initiation until 30 days post treatment discontinuation for all patients. Range of cycles of treatment completed by patients was 1-47 where one cycle equals 28 days on bevaciumab every 2 week schedule and 42 days on bevacizumab every 3 weeks. Longest time any patient was on treatment was 5 years. Data that has been collected in the database is reported here. There is still some data entry of other adverse events for a few patient being completed and this Section will be updated accordingly when all data is entered and available for reporting (if applicable).
Vascular disorders Hypertension	42.0% 21/50 • Adverse events were collected from the time of treatment initiation until 30 days post treatment discontinuation for all patients. Range of cycles of treatment completed by patients was 1-47 where one cycle equals 28 days on bevaciumab every 2 week schedule and 42 days on bevacizumab every 3 weeks. Longest time any patient was on treatment was 5 years. Data that has been collected in the database is reported here. There is still some data entry of other adverse events for a few patient being completed and this Section will be updated accordingly when all data is entered and available for reporting (if applicable).
Vascular disorders Vascular other	4.0% 2/50 • Adverse events were collected from the time of treatment initiation until 30 days post treatment discontinuation for all patients. Range of cycles of treatment completed by patients was 1-47 where one cycle equals 28 days on bevaciumab every 2 week schedule and 42 days on bevacizumab every 3 weeks. Longest time any patient was on treatment was 5 years. Data that has been collected in the database is reported here. There is still some data entry of other adverse events for a few patient being completed and this Section will be updated accordingly when all data is entered and available for reporting (if applicable).

Additional Information

Priya Kumthekar, MD

Northwestern University

Email: Priya.Kumthekar@nm.org

Results disclosure agreements

• Principal investigator is a sponsor employee
• Publication restrictions are in place